Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference
Dynavax Technologies Corporation (Nasdaq: DVAX) will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dynavax Technologies Corporation (Nasdaq: DVAX) will present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference on March 9-10, 2021. CEO Ryan Spencer will lead the presentation, which will be available on demand starting at 7:00 a.m. E.T. on March 9, accessible via the Investors section of the company’s website. Dynavax specializes in developing vaccines, having commercialized HEPLISAV-B®, a hepatitis B vaccine, and is advancing CpG 1018 as a vaccine adjuvant for various collaborations.
Details
News Market Reaction – DVAX
The recorded move for DVAX in the trading session of this news was -2.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., March 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference being held March 9-10, 2021.
The on demand presentation will be available, beginning Tuesday, March 9, 2021 at 7:00 a.m. E.T. and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and Europe for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.
Contacts:
Nicole Arndt
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-virtual-2021-global-life-sciences-conference-301237827.html
SOURCE Dynavax Technologies
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.